A Multicenter, Open, Single Arm Dose-escalation and Dose-expansion Study: to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of FCN-437c Alone or in Combination With Letrozole in ER+/ HER2- Advanced Breast Cancer
Latest Information Update: 07 Jul 2022
At a glance
- Drugs FCN 437 (Primary) ; Fulvestrant; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors Ahon Pharmaceutical
- 07 Jun 2022 Results (as of November 26, 2021; n=29) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 09 Jun 2021 Results (data cut-off date August 10, 2020; n=17) evaluating safety profile of FCN-437, published in the Investigational New Drugs
- 10 Apr 2021 Results from phase Ia part of this study (n=17; as of 10 Aug 2020) presented at the 112th Annual Meeting of the American Association for Cancer Research